Pre-Open Stock Movers 11/29: (KRYS) (ADGI) (TWTR) Higher; (MRK) (UPS) Lower (more...)
- Wall Street rallies, capping frenetic week with best day of the year
- Apple (AAPL) Stock Soars on Another Robust Quarter Fueled by Monster iPhone and Services Numbers, Analysts Raise PTs
- BofA Raises Inflation Forecasts for 2022, Expects Fed to Hike 7 Times in 2022
- Netflix (NFLX) CEO Hastings Buys ~$20 Million in Stock Following Sell-Off, Ackman's Big Bet
- Oil hits 7-year peak on political risks, supply crunch
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Pre-Open Stock Movers:
Krystal Biotech, Inc., (NASDAQ: KRYS) 142.6% HIGHER; announced positive topline results from the pivotal GEM-3 trial of investigational beremagene geperpavec (B-VEC), now known as VYJUVEKTM, for the treatment of dystrophic Epidermolysis Bullosa (dystrophic EB). The primary endpoint of the trial evaluated complete wound healing of topical VYJUVEKTM compared to placebo at six-month timepoints and met statistical significance. VYJUVEKTM is the first non-invasive, topical and redosable gene therapy in development, and the only genetically corrective approach to treat dystrophic EB that has successfully completed a double blinded Phase 3 trial.
Adagio Therapeutics, Inc., (Nasdaq: ADGI) 25.8% HIGHER; provided information related to the potential of its lead SARS-CoV-2 antibody, ADG20, to address the Omicron SARS-CoV-2 variant, and other known variants of concern. ADG20 is an investigational monoclonal antibody (mAb) product candidate designed to provide broad and potent neutralizing activity against SARS-CoV-2, including variants of concern, for the prevention and treatment of COVID-19 with potential duration of protection for up to one year in a single injection. Upgraded to Overweight at Morgan Stanley.
Applied DNA Sciences, Inc. (NASDAQ: APDN) 21.1% HIGHER; announced its COVID-19 diagnostic strategy in response to the emergence of Omicron (B.1.1.529), a newly identified SARS-CoV-2 variant of concern. The Company plans to introduce its Linea 2.0 COVID-19 Assay (Linea 2.0), a new RT-PCR assay for the SARS-CoV-2 E and N genes that builds on the Companys established COVID-19 line of diagnostics, after submission of its validation data to the New York State Department of Health (NYSDOH) in the next few days.
Moderna (NASDAQ: MRNA) 12.3% HIGHER; adds to gains on new Omicron variant.
Twitter (NYSE: TWTR) 10.7% HIGHER; CEO Jack Dorsey is expected to step down, according to a report from CNBC's David Faber.
BioNTech SE (NASDAQ: BNTX) 6.7% HIGHER; adds to gains on new Omicron variant.
Bumble Inc. (NASDAQ: BMBL) 3.7% HIGHER; Raymond James upgraded from Market Perform to Outperform with a price target of $48.00.
Square, Inc. (NYSE: SQ) 3.2% HIGHER; reports Jack Dorsey to step down as CEO of Twitter.
Merck (NYSE: MRK) 3% LOWER; Citi downgraded from Buy to Neutral with a price target of $85.00 (from $105.00).
UPS (NYSE: UPS) 0.8% LOWER; Deutsche Bank downgraded from Buy to Hold with a price target of $221.00 (from $253.00).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pre-Open Stock Movers 01/28: (CLFD) (PRVB) (TEAM) Higher; (HOOD) (WDC) (CVX) Lower (more...)
- Tesla's (TSLA) Elon Musk Slams Biden Following GM (GM) and Ford (F) White House Meeting
- Pre-Open Stock Movers 1/21: (LLNW) (PTON) (UAA) Higher; (NFLX) (RIOT) (MARA) Lower (more...)
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesDeutsche Bank, David Faber, Citi, Raymond James, Morgan Stanley, Twitter, Pre-Open Losers, Pre-Open Winners, Pre Market Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!